FDA grants FELIQS fast track status for FLQ-101 in ROP preventive treatment

FDA grants FELIQS fast track status for FLQ-101 in ROP preventive treatment

FELIQS, a multinational clinical-stage biopharmaceutical firm headquartered in Japan, has announced that its leading asset, FLQ-101, has received Fast Track designation from the U.S. Food and Drug Administration (FDA). This groundbreaking small molecule is designed to prevent retinopathy of prematurity (ROP), a severe eye disorder impacting premature neonates. FELIQS is set to initiate its Phase […]